BPC-157 API and Research Peptide Supplier

What is BPC-157?

BPC-157 (Body Protection Compound 157, also designated PL 14736) is a synthetic pentadecapeptide of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The sequence corresponds to a partial fragment derived from a protein identified in human gastric juice. Its molecular formula is C62H98N16O22 with a molecular weight of approximately 1419.56 g/mol (CAS 137525-51-0).

In preclinical research the peptide has been studied for cytoprotective, angiogenic and tissue-repair related effects, predominantly in animal and in-vitro models. The current regulatory position is unambiguous: BPC-157 is not approved by the FDA, EMA or any other drug regulatory agency for human therapeutic use. In 2023 the US FDA placed it in Category 2 of its interim policy on bulk substances used in compounding, citing immunogenicity and impurity concerns, and it has no USP/NF monograph. No efficacy or therapeutic-benefit claims are established for this molecule.

How BPC-157 Is Produced & Characterised

As a 15-residue linear peptide rich in proline (three consecutive Pro residues) and acidic Asp/Glu residues, BPC-157 presents synthesis challenges around coupling efficiency, aspartimide formation and the resolution of closely related deletion and isomerisation sequences. For peptides of this class, the typical industry route is Fmoc solid-phase peptide synthesis (SPPS) with controlled coupling chemistry to suppress these side reactions, followed by purification on preparative HPLC (commonly dynamic axial compression, DAC, columns) to isolate the target sequence from related impurities, and lyophilisation to a stable powder.

Characterisation generally relies on UPLC/HPLC for purity, LC-MS for identity and minor structural-variant profiling, and determination of water content, counter-ion (salt) content, residual solvents and peptide content so the material is fully defined.

Regulatory Context

BPC-157 is not an approved active pharmaceutical ingredient. It carries no USP/NF monograph and no marketing authorisation from the FDA, EMA or any other drug regulatory agency for therapeutic use. In 2023 the US FDA placed BPC-157 in Category 2 of its interim policy on bulk drug substances used in compounding, citing immunogenicity and impurity concerns.

Because no regulatory therapeutic pathway exists for this molecule, it is encountered only as a research chemical or reference standard. Nothing on this page is medical advice.

Research supply from Winhycare Pharma

Winhycare Pharma supplies research-grade BPC-157 to research organisations and individual researchers for research and development purposes. Material is supplied at high purity (>99%) under stringent quality control with QC documentation, in secure packaging through global standard logistics, with dedicated technical assistance from our team. We focus on consistent quality and purity, reliable and timely supply, confidential and professional service, and long-term partnerships.

Research use only. Not for human or veterinary use, and not for use in food, drugs, medical devices or cosmetics.

To enquire, tell us the quantity you need, the purity grade, the documentation you require and the destination country. The buyer is responsible for complying with the import and use regulations that apply to BPC-157 in their country.